(Q84864312)

English

Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen

scientific article published on 13 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

mucopolysaccharidosis VI

1 reference

based on heuristic

inferred from title

3

object named as

Joleen White

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

9

object named as

John J Hopwood

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Dyane Auclair

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

John Finnie

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Timothy Nielsen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria Fuller

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Emil Kakkis

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Alphonsus Cheng

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Charles A O'Neill

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

13 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

99

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

132-141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelopathy due to diffuse thickening of the cervical dura mater in Maroteaux-Lamy syndrome: report of a case

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Compressive myelopathy associated with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelography Features of Mucopolysaccharidoses: A New Sign

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelopathy associated with Maroteaux-Lamy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Magnetic resonance imaging in the diagnosis of the cranio-cervical manifestations of the mucopolysaccharidoses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Lysosomal storage diseases and the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Mutational analysis of 105 mucopolysaccharidosis type VI patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Immunochemical characterization of feline and human N-acetylgalactosamine 4-sulfatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Complications of interlaminar cervical epidural steroid injections: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Cervical epidural steroid injection with intrinsic spinal cord damage. Two case reports

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Identifiers

10.1016/J.YMGME.2009.10.002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84864312&oldid=1871029416"